Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AKBA with free AI briefings, catalyst countdowns, and dilution alerts.

AKBA · Akebia Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$159.3M Cash on Hand
CF+ Cash Runway
9.9% Short Interest
$3 Analyst Target (6)
Follow AKBA by email Get an email when AKBA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AKBA, unsubscribe in one click. Privacy

📣 What AKBA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Standard of care phosphate-lowering therapy Hyperphosphatemia Phase 4 · NCT04922645 Completed
Ferric Citrate 1 gram Oral Tablet Hyperphosphatemia Phase 4 · NCT04922645 Completed
Vadadustat 900mg Nonintubated Acute Respiratory Distress Syndrome (ARDS) Phase 2/3 · NCT07086755 Recruiting
Vadadustat 1200mg Nonintubated Acute Respiratory Distress Syndrome (ARDS) Phase 2/3 · NCT07086755 Recruiting
Vadadustat (AKB-6548) Anemia of Chronic Kidney Disease Phase 3 · NCT06901505 Completed
Mircera® Anemia Associated With Chronic Kidney Disease (CKD) Phase 3 · NCT04707768 Completed
Ferric Citrate 1 GM Oral Tablet [AURYXIA] Anemia, Iron Deficiency Phase 3 · NCT05085275 Completed
Erythropoiesis-Stimulating Agent (ESA) Anemia of Chronic Kidney Disease Phase 3 · NCT06901505 Completed
Erythropoiesis Stimulating Agent Anemia of Chronic Kidney Disease Phase 3 · NCT06520826 Completed
ADX-097 IgA Nephropathy Phase 2 · NCT06419205 Recruiting
Vadadustat TIW Anemia Phase 2 · NCT03799627 Completed
Praliciguat (Part B) Focal Segmental Glomerulosclerosis Phase 2 · NCT07268638 Recruiting
Praliciguat (Part A) Focal Segmental Glomerulosclerosis Phase 2 · NCT07268638 Recruiting
IW-1973 Type 2 Diabetes Mellitus With Diabetic Nephropathy Phase 2 · NCT03217591 Completed
Probenecid Drug Interaction Potentiation Phase 1 · NCT03801746 Completed
Adefovir Drug Interaction Potentiation Phase 1 · NCT03801759 Completed

Also used in these trials (approved or third-party drugs, not AKBA's own candidates): Darbepoetin Alfa, Epoetin Alfa, Calcium Acetate, Celecoxib, Digoxin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AKBA holds $159.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AKBA files for a raise →

👥 Who Owns AKBA

Insiders 2.9% Institutions (210 holders) 41.4% Public and other holders 55.7%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 19,219,819 6.92% 2025-12-31
Vanguard Capital Management LLC Institution (13F) 11,327,392 4.08% 2026-09-30
Acadian Asset Management. LLC Institution (13F) 8,970,363 3.23% 2026-09-30
Geode Capital Management, LLC Institution (13F) 6,345,692 2.29% 2026-09-30
AQR Capital Management, LLC Institution (13F) 6,294,526 2.27% 2026-09-30
Two Sigma Investments, LP Institution (13F) 6,069,090 2.19% 2026-09-30
State Street Corporation Institution (13F) 5,295,074 1.91% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 4,423,717 1.59% 2026-09-30
John P. Butler
CEO and President, Director · +3.04M options
Insider 3,878,492 1.40% 2026-08-06
Vanguard Portfolio Management LLC Institution (13F) 3,537,072 1.27% 2026-09-30
Steven Keith Burke
SVP, Chief Medical Officer · +612,300 options
Insider 948,432 0.34% 2026-02-02
Erik Ostrowski
SVP, CFO, CBO & Treasurer · +320,000 options
Insider 616,616 0.22% 2026-06-29

Share count 277,663,875 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-08-06
filed 2026-08-10
Butler John P.
Option exercise (M) 350,000 $0.63 3,718,564
2026-08-06
filed 2026-08-10
Butler John P.
Option exercise (M) 350,000 – –
2026-06-29
filed 2026-07-01
Ostrowski Erik
Sale (S) 56,019 $1.11 616,616
2026-06-17
filed 2026-06-22
ROGERS MICHAEL W
Award (A) 35,700 – 197,429
2026-06-17
filed 2026-06-22
ZUMWALT LEANNE M
Award (A) 35,700 – 145,100

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full AKBA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AKBA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.